Homeopathy for COVID-19 in primary care:A randomized,double-blind,placebo-controlled trial(COVID-Simile study)  

作　　者：Ubiratan Cardinalli Adler Maristela Schiabel Adler Ana Elisa Madureira Padula Livia Mitchiguian Hotta Amarilysde Toledo Cesar JoséNelson Martins Diniz Helen de Freitas Santos Edson Zangiacomi Martinez 

机构地区：[1]Department of Medicine,Federal University of São Carlos,São Carlos 13565-905,Brazil [2]Homeopathy Solidarity Outpatient Extension Program,Mackenzie Presbyterian University,São Paulo 01302-907,Brazil [3]Municipal Center for Integrative and Complementary Practices in Health,Guarulhos 07023-051,Brazil [4]HN-Cristiano Institute,São Paulo 02013-001,Brazil [5]School Health Unit,Federal University of São Carlos,Sao Carlos 13565-905,Brazil [6]Federal Institute of Education,Science and Technology of São Paulo,Birigui 16201-407,Brazil [7]Department of Social Medicine,Ribeirão Preto Medical School,University of Sao Paulo,Ribeirao Preto 14049-900,Brazil

出　　处：《Journal of Integrative Medicine》2022年第3期221-229,共9页结合医学学报（英文版）

摘　　要：Background:Different homeopathic approaches have been used as supportive care for coronavirus disease 2019(COVID-19)cases,but none has been tested in a clinical trial.Objectives:To investigate the effectiveness and safety of the homeopathic medicine,Natrum muriaticum LM2,for mild cases of COVID-19.Design,setting,participants,and interventions:A randomized,double-blind,two-armed,parallel,singlecenter,placebo-controlled clinical trial was conducted from June 2020 to April 2021 in S?o-Carlos,Brazil.Participants aged>18 years,with influenza-like symptoms and positive result from a real-time polymerase chain reaction test for severe acute respiratory syndrome coronavirus 2 were recruited and randomized(1:1)into two groups that received different treatments during a period of at-homeisolation.One group received the homeopathic medicine Natrum muriaticum,prepared with the second degree of the fifty-millesimal dynamization(LM2;Natrum muriaticum LM2),while the other group received a placebo.Outcome measures:The primary endpoint was time until recovery from COVID-19 influenza-like symptoms.Secondary measures included a survival analysis of the number and severity of COVID-19 symptoms(influenza-like symptoms plus anosmia and ageusia)from a symptom grading scale that was informed by the participant,hospital admissions,and adverse events.Kaplan-Meier curves were used to estimate time-to-event(survival)measures.Results:Data from 86 participants were analyzed(homeopathy,n=42;placebo,n=44).There was no difference in time to recovery between two groups among participants who were reporting influenzalike symptoms at the beginning of monitoring(homeopathy,n=41;placebo,n=41;P=0.56),nor in a sub-group that had at least 5 moderate to severe influenza-like symptoms at the beginning of monitoring(homeopathy,n=15;placebo,n=17;P=0.06).Secondary outcomes indicated that a 50%reduction in symptom score was achieved significantly earlier in the homeopathy group(homeopathy,n=24;placebo,n=25;P=0.04),among the participants with a basal symptom s

关 键 词：HOMEOPATHY COVID-19 Primary care Natrum muriaticum Randomized controlled trial 

分 类 号：R563.1[医药卫生—呼吸系统]